Nabriva Therapeutics
Manufacturing · Ireland · 51-200 Employees
View Company Info for Free
Overview
Headquarters
25-28 N Wall Quay Ifsc 1, Dublin, Dublin...Phone Number
+353 16492000Website
www.nabriva.comRevenue
$34.4 MillionStock Symbol
NBRVIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
2
1
1
1
1
About Nabriva Therapeutics
Founded in 2006, Nabriva Therapeutics is a biopharmaceutical company that engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company is headquartered in Dublin, Ireland.Explore more
Nabriva Therapeutics Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Nabriva Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on Nabriva Therapeutics recently announced quarterly report
Click to see if Nabriva Therapeutics had a recent Job posting/layoffs
Check out if Nabriva Therapeutics is spiking on competitors!
Congratulate Masked Content for being promoted to Masked Content at Nabriva Therapeutics
Check if Nabriva Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Nabriva Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Nabriva Therapeutics launches new products
Funding: Get notified immidiatlly once Nabriva Therapeutics has new funding data
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Company Profile Activity
Activity Insights
Nabriva Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Nabriva Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Nabriva Therapeutics.
Nabriva Therapeutics financials insights
Gather financial insights about Nabriva Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2015
Stock Offering
$92.3M
Nabriva Therapeutics Tech Stack
A closer look at the technologies used by Nabriva Therapeutics
See more technologies
Most Recent Scoops
Left Company
Executive Move
Executive Move
Board of Directors
Earnings
Event
Earnings, Events
Left Company
Executive Move
Mersedeh Miraliakbari, Vice President, Regulatory Affairs, has left the organization to join NEW Upstream Biosciences as Senior VP, Regulatory Affairs & Quality.
New Hire
Executive Move
New Hire
Nabriva Therapeutics News & Media
Meitheal Pharmaceuticals Expands Specialty Biopharmaceuticals Portfolio with Acquisition of CONTEPO™ (Fosfomycin for Injection) from Nabriva Therapeutics
CHICAGO--(BUSINESS WIRE)--Meitheal Pharmaceuticals, Inc. (“Meitheal”), a fully integrated biopharmaceutical company based in Chicago and focused on the development and commercialization of generic injectables, fertility, biologic, and branded products, today announced it has acquired North America rights to CONTEPO™ (fosfomycin for injection) from Nabriva Therapeutics. CONTEPO™ is a novel, intravenous (IV), broad spectrum antibiotic with demonstrated activity against most multi-drug resistant (NABRIVA THERAPEUTICS PLC MANAGEMENT'S DISCUSSION AND ANALYSIS OF ...
You should read the following discussion and analysis of our financial condition and results of operations together with our historical consolidated financial statements and the related notes thereto... | April 17, 2023Nabriva Therapeutics Announces Positive Topline Results from Phase 1 Trial of XENLETA® (lefamulin) in Adult Patients with Cystic Fibrosis
- PK Data and Safety Profile Consistent with Previous Studies in Healthy Subjects –Nabriva Therapeutics plc (NBRV) Q3 2022 Earnings Call Transcript
Nabriva Therapeutics plc (NASDAQ:NASDAQ:NBRV) Q3 2022 Earnings Conference Call November 10, 2022 4:30 PM ET Company Participants Daniel Dolan - CFO Theodore Schroeder - CEO Conference Call...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Nabriva Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2006, Nabriva Therapeutics is a biopharmaceutical company that engages in the development and commercialization of novel anti-infective agents to treat serious infections. The company is headquartered in Dublin, Ireland.... Read More
